DIA 2016 Annual Meeting

Component Type: Workshop
Level: Basic

Drug developers, regulators, and payers are increasingly relying on large, linked, and networked databases to discover and test new therapies; inform regulatory and funding decisions; monitor therapies in practice and fine tune therapeutic approaches. The use of such “big data” resources is scientifically exciting but raises a number of ethical issues relating to participant consent and confidentiality; ownership, and benefit sharing; and effects on clinical trials, regulatory and funding processes, and the physician-patient relationship. This session will include an exercise to explore the ethical issues raised by biomedical research that uses “big data” resources.

**Due to session format, seating will be limited to 50 participants and available on a first come, first served basis. Once all seats are occupied, DIA will be required to close the session, and no more participants will be admitted. Interested attendees are encouraged to arrive early in order to ensure seating.

Learning Objectives

Recognize that there are many different kinds of “big data” with many different applications in public health and biomedicine; Discuss the key ethical issues arising from research involving “big data,” including consent, confidentiality, ownership, benefit sharing, and effects on clinical trials, regulatory and funding processes and the physician-patient relationship; Express whether, when and how “big data” research should be conducted so it is ethically sound.

Chair

Wendy Louise Lipworth